Company Profile

Industry Sector: Pharmaceutical and Biologics

Company Overview: Nanotherapeutics is a privately-owned Florida company with a proven track record in GMP manufacturing and preclinical to clinical product development. Nanotherapeutics is pioneering the applications of novel particle delivery technologies in the development and manufacturing of novel pharmaceutical and biomedical products. The company employs several platform technologies to manipulate and enhance the properties of drugs.

Nanotherapeutics’ technologies address these issues by:
- Providing non-invasive routes of administration, i.e. oral or inhaled.
- Enhancing the systemic absorption (bioavailability) of compounds.

Target Market(s): Nanotherapeutics partners for marketing and distribution of its pharmaceutical and biologic products to the public, including hospital-based therapies and doctor-prescribed drug regimens.

Management

Leadership:
James D. Talton, Ph.D., President & CEO
Dennis Tomisaka, M.S., MBA, V.P., Operations & Product Dev.
Barbel Eppler, Ph.D., V.P., Preclinical & QA
James Kirk, Ph.D., MBA, V.P., Research and Development
John Abernethy, M.D., Medical Director
Dennis Kristof, CMA, MBA, Controller

Board of Directors:
Weaver H. Gaines, 35 years of executive, legal, and entrepreneurial experience
Robert Hennessey, executive with Penwest, Abbott, SmithKline, and Merck.
James M. Matthew, experienced financial executive, CFO of Jesup & Lamont.
James R. Butler, ex-President of Alza International, Advisor to Capnia, Reliant
Sean McConnell, MSM, LLP, and Dir. of HR, Modern Business Associates, Inc.
James Fitz-Gerald, Ph.D., Asst. Professor, Dept. of Materials Sci. & Eng., UVA

Key Value Drivers

Technology*: The key benefit of our NanoBUP™ rapid-release swallowed capsule product is that it improves the ability of the body to efficiently absorb buprenorphine with less variability then sublingual administration.
- NanoBUP™ capsule bioavailability 5-7x compared to buprenorphine solution
- Potential to increase use, including withdrawal and detoxification in opiate-abusers.

Competitive Advantage: Nanotherapeutics’ technologies can improve the release rate and enhance both the rate and extent of drug uptake, thus increasing bioavailability. The consequences of these changes include more consistent drug therapy with potentially reduced dose and dose frequency requirements and fewer side effects.

Plan & Strategy: Nanotherapeutics has 1 FDA approved injectable product and a pipeline of partnered and internal programs. Nanotherapeutics partners for marketing and distribution.

*Technology funded by NIDA and being commercialized under the NIH-CAP

Product Pipeline

Current Products

<table>
<thead>
<tr>
<th>Medical Devices</th>
<th>R&amp;D</th>
<th>Animal Studies</th>
<th>510K</th>
<th>Market</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Origen DBT™</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Blackstone / Orthofx</td>
</tr>
</tbody>
</table>

Product Pipeline

<table>
<thead>
<tr>
<th>Pharmaceuticals</th>
<th>R&amp;D</th>
<th>Pre-Clin</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>NDA</th>
<th>Market</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>NanoDOX™</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NanoBUP™</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NanoGENT™</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Internal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compound 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Completed | In Progress